MannKind Co. (NASDAQ:MNKD – Get Free Report) has been given an average rating of “Buy” by the seven analysts that are covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $8.67.
A number of equities analysts have recently commented on MNKD shares. Leerink Partners started coverage on MannKind in a research report on Monday, September 9th. They set an “outperform” rating and a $8.00 price objective for the company. Leerink Partnrs raised MannKind to a “strong-buy” rating in a research report on Monday, September 9th. Finally, Oppenheimer boosted their price objective on MannKind from $10.00 to $12.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 28th.
Check Out Our Latest Report on MannKind
Insider Activity at MannKind
Institutional Investors Weigh In On MannKind
Large investors have recently modified their holdings of the company. Susquehanna Fundamental Investments LLC acquired a new stake in shares of MannKind in the first quarter valued at approximately $450,000. SG Americas Securities LLC purchased a new stake in shares of MannKind during the third quarter worth approximately $546,000. Bank of New York Mellon Corp raised its stake in shares of MannKind by 14.4% during the second quarter. Bank of New York Mellon Corp now owns 915,248 shares of the biopharmaceutical company’s stock worth $4,778,000 after purchasing an additional 115,390 shares during the last quarter. Millennium Management LLC raised its stake in shares of MannKind by 189.8% during the second quarter. Millennium Management LLC now owns 4,744,519 shares of the biopharmaceutical company’s stock worth $24,766,000 after purchasing an additional 3,107,598 shares during the last quarter. Finally, Dimensional Fund Advisors LP purchased a new stake in shares of MannKind during the second quarter worth approximately $1,524,000. 49.55% of the stock is owned by institutional investors and hedge funds.
MannKind Price Performance
Shares of MannKind stock opened at $6.49 on Thursday. The business has a 50-day moving average of $6.18 and a 200 day moving average of $5.34. MannKind has a 12 month low of $3.17 and a 12 month high of $6.92. The stock has a market capitalization of $1.77 billion, a price-to-earnings ratio of 216.33 and a beta of 1.31.
MannKind (NASDAQ:MNKD – Get Free Report) last announced its earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.04. MannKind had a negative return on equity of 11.97% and a net margin of 4.73%. The company had revenue of $72.39 million during the quarter, compared to analysts’ expectations of $64.81 million. During the same period last year, the business posted ($0.02) EPS. MannKind’s revenue for the quarter was up 48.9% on a year-over-year basis. Equities research analysts anticipate that MannKind will post 0.11 earnings per share for the current year.
About MannKind
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.
See Also
- Five stocks we like better than MannKind
- How to Calculate Return on Investment (ROI)
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- What Are Growth Stocks and Investing in Them
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.